Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354 in a randomized, controlled, multicenter Phase 3 clinical trial, for platinum-resistant ovarian cancer with HER2 expression.